Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Grows By 42.2%

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 22,900 shares, an increase of 42.2% from the March 31st total of 16,100 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average daily trading volume, of 22,000 shares, the short-interest ratio is currently 1.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in vTv Therapeutics stock. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) by 12.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,634 shares of the biotechnology company's stock after buying an additional 1,327 shares during the quarter. Geode Capital Management LLC owned 0.36% of vTv Therapeutics worth $158,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.51% of the company's stock.

vTv Therapeutics Price Performance

NASDAQ:VTVT traded up $1.41 during trading hours on Monday, reaching $21.92. 4,279 shares of the company were exchanged, compared to its average volume of 23,248. The business has a 50 day moving average of $18.24 and a 200 day moving average of $16.48. vTv Therapeutics has a 1-year low of $12.12 and a 1-year high of $29.01. The company has a market capitalization of $69.93 million, a P/E ratio of -4.96 and a beta of 0.77.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.32. The company had revenue of $0.02 million during the quarter.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. StockNews.com initiated coverage on shares of vTv Therapeutics in a research report on Wednesday, April 16th. They set a "sell" rating for the company. HC Wainwright assumed coverage on vTv Therapeutics in a report on Wednesday, April 9th. They set a "buy" rating and a $36.00 target price for the company.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.